ClinConnect ClinConnect Logo
Search / Trial NCT00001093

Outcomes of Anti-HIV Therapy During Early HIV Infection

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of May 10, 2025

Completed

Keywords

Immunity, Cellular Sexual Partners Treatment Outcome Anti Hiv Agents Viral Load Acute Infection

ClinConnect Summary

Although many researchers have recommended initiation of aggressive antiretroviral therapy as soon as possible after HIV infection occurs, the tolerability and efficacy of this approach has not been systemically evaluated. Many features of primary HIV pathogenesis are incompletely understood. A more complete understanding of immune dynamics and viral pathogenesis during primary HIV infection is critical to determine optimal treatment intervention strategies. This study will evaluate the outcomes of potent antiretroviral therapy initiated at different stages of primary HIV infection.

Thirty...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients may be eligible for this study if they:
  • Are at least 13 years old.
  • Have acute or early HIV infection. The stage of HIV infection will depend on the results from certain lab tests.
  • Exclusion Criteria
  • Patients will not be eligible for this study if they:
  • Are pregnant or breast-feeding.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

San Diego, California, United States

Los Angeles, California, United States

San Francisco, California, United States

Patients applied

0 patients applied

Trial Officials

Susan Little

Principal Investigator

James Kahn

Principal Investigator

Eric Daar

Principal Investigator

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials